| Nov 7 |
Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
|
| Nov 2 |
Here's What Analysts Are Forecasting For Pulmonx Corporation (NASDAQ:LUNG) After Its Third-Quarter Results
|
| Nov 1 |
Pulmonx Third Quarter 2024 Earnings: EPS Beats Expectations
|
| Oct 31 |
Pulmonx Corp (LUNG) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
|
| Oct 31 |
Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript
|
| Oct 30 |
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
|
| Oct 30 |
Pulmonx GAAP EPS of $0.36 beats by $0.81, revenue of $20.4M beats by $0.12M
|
| Oct 30 |
Pulmonx Reports Third Quarter 2024 Financial Results
|
| Oct 16 |
Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
|
| Sep 9 |
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
|
